



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/770,875	01/26/2001	Witold Cieplak	2026-4253US7	6669

7590 09/25/2002

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154

[REDACTED] EXAMINER

BUGAISKY, GABRIELE E

ART UNIT	PAPER NUMBER
1653	8

DATE MAILED: 09/25/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application N .	Applicant(s)
	09/770,875 Examiner Gabriele E. BUGAISKY	CIEPLAK, WITOLD Art Unit 1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 5 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) 5 is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.
 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.
 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) The translation of the foreign language provisional application has been received.
 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>1 1/2</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Priority

Upon review, it appears that the inventorship of record of 07/311612 is not the same as that of the instant application. The Examiner has reviewed 07/311, 612; no papers requesting correction of inventorship for that parent application could be found in the file. Priority to that application cannot be granted unless the inventorship is changed.

Specification

The disclosure is objected to because of the following informalities: Table 2 (pages 16 and 16a) is a photocopy of a sequence with extremely small, nearly illegible font (many of the "G"s are indistinguishable from the "C"s. It is highly unlikely that a good image could be generated for publication from this table. Applicant is requested to provide a more legible copy of this information.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 5 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Recitation of amino acid position without reference to a sequence renders a claim indefinite.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in
 - (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or
 - (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).

Claim 5 is rejected under 35 U.S.C. 102(b) as being anticipated by BURNETTE *et al.*

(Science) As priority cannot be granted to the 2/15/199 filing date of 07/311,812 unless there is at least one inventorship in common, the reference qualifies under section (b) of the statute.

Should the priority be perfected, then this rejection would qualify under section (a).. Table 1 describes a S1 mutant at arg9 (mutant 4-1); the reference is anticipatory for the claimed subject matter because it provides protein expressed from a mutated gene encoding an S1 subunit of pertussis toxin comprising a substitution at arg9 to lys9.

Claim 5 is rejected under 35 U.S.C. 102(e) as being anticipated by W. N.BURNETTE (US patent 5773600). The reference is anticipatory for the claimed subject matter because it provides protein expressed from a mutated gene encoding an S1 subunit of pertussis toxin comprising a substitution at arg9 to lys9 (see e.g., column 16, lines 6-45.)

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over PIZZA *et al.* (US patent 5925546). The reference provides for recombinant production of a pertussis S1 subunit with a mutation at Arg9 and Tyr8; thus, the mutated subunit of the reference comprises a mutation at Arg9. The reference does not specifically teach the R>K substitution, but does suggest (see e.g., column 2, lines 47-67) the substitution with any amino acid that differs from the one to be mutated. It would have been obvious to one of ordinary skill in the art at the time of the invention, to utilize any amino acid, including lysine, to substitute for the Arg9 of the S1 subunit of pertussis, and to subsequently recombinantly produce a subunit of altered toxicity without altering the immunologic properties. Amendment to recite a single site substitution at arg 9 could overcome this rejection.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 5 is provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 11, 13 and 15-16 of copending Application No. 07/542149. Although the conflicting claims are not identical, they are not patentably distinct from each other because it is obvious to use a transformed cell containing a plasmid encoding a specific protein in a method of making that protein. In general, a method of making a protein by recombinant means is not deemed patentably distinct from the isolated DNA, plasmid, and transformed host cells.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion


No claim is allowed.

US patent 5244657 (Klein *et al.*) describes an immunoprotective genetically-detoxified mutant of pertussis holotoxin wherein ARG.9 is replaced by LYS9. in the S1 sub-unit in the native pertussis toxin .

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gabriele E. BUGAISKY whose telephone number is (703)308-4201. The examiner can normally be reached on 8:15-12:15 M, 8:15-1:15 Tu-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher SF Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308-4242 for regular communications and 703 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 708 308-0196.



Gabriele E. BUGAISKY
Primary Examiner
Art Unit 1653

September 23, 2002

GABRIELLE BUGAISKY
PRIMARY EXAMINER